[Positron emission tomography in oncology]

Area of Science:

• Nuclear medicine and molecular imaging
• Oncological diagnostics and therapy

Context:

• Positron emission tomography (PET) is a highly sensitive, noninvasive imaging modality.
• PET is integral to oncological diagnostics and therapy management, influencing treatment decisions.
• Examples include guiding treatment for Hodgkin lymphomas and reducing surgeries in lung cancer.

Purpose:

• To highlight the indispensable role of molecular PET imaging in personalized cancer treatments.
• To emphasize the potential of novel radiotracers for diagnostics and targeted therapies.
• To showcase advancements in radioligands, such as those targeting prostate-specific membrane antigen for prostate cancer.

Summary:

• PET imaging characterizes metabolic processes and molecular targets noninvasively.
• PET assessments directly impact treatment escalation/de-escalation and surgical decisions in oncology.
• Development of new radiotracers for specific cell surface structures offers significant diagnostic and therapeutic potential.

Impact:

• Molecular PET imaging is essential for developing personalized cancer treatments.
• Targeted radiotracers, like those for prostate-specific membrane antigen, advance precision oncology.
• PET facilitates more accurate diagnosis, tailored therapy, and improved patient outcomes in cancer care.